Q3 Earnings Estimate for CVKD Issued By Noble Financial

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Investment analysts at Noble Financial issued their Q3 2026 earnings per share estimates for shares of Cadrenal Therapeutics in a research note issued on Monday, August 17th. Noble Financial analyst R. Leboyer expects that the company will earn ($0.94) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.37) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.91) EPS and FY2027 earnings at ($3.55) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.28.

CVKD has been the topic of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $13.00.

Cadrenal Therapeutics Stock Down 2.8%

CVKD opened at $1.71 on Wednesday. The stock has a market capitalization of $5.84 million, a price-to-earnings ratio of -0.35 and a beta of 1.84. Cadrenal Therapeutics has a twelve month low of $1.64 and a twelve month high of $14.64. The company has a 50-day simple moving average of $2.61 and a 200 day simple moving average of $4.72.

Insider Buying and Selling at Cadrenal Therapeutics

In other news, CEO Quang X. Pham sold 9,029 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $3.05, for a total value of $27,538.45. Following the sale, the chief executive officer directly owned 105,989 shares in the company, valued at approximately $323,266.45. This trade represents a 7.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 87,726 shares of company stock valued at $333,575. Company insiders own 14.59% of the company’s stock.

Hedge Funds Weigh In On Cadrenal Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its position in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics in the 3rd quarter valued at $103,000. DRW Securities LLC bought a new position in shares of Cadrenal Therapeutics in the 4th quarter valued at $171,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Cadrenal Therapeutics during the 3rd quarter valued at $274,000. Institutional investors own 7.92% of the company’s stock.

Key Stories Impacting Cadrenal Therapeutics

Here are the key news stories impacting Cadrenal Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2028 EPS forecast to a loss of $1.92 from a loss of $2.33, suggesting the analyst expects longer-term losses to narrow as the company progresses toward potential commercialization or revenue generation.
• Positive Sentiment: Noble Financial’s FY2026 EPS estimate of a $3.91 loss is less pessimistic than the broader consensus estimate of a $4.37 loss. Noble also projects losses improving to $3.55 per share in FY2027, although the company would remain deeply unprofitable.
• Neutral Sentiment: Noble Financial expects Cadrenal Therapeutics to post losses of $0.94 per share in Q3 2026 and $0.89 per share in Q4 2026, with additional quarterly losses of $0.88 to $0.93 projected throughout 2027. These estimates point to ongoing operating expenses without near-term profitability.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a $3.92 loss from $3.19 and cut its FY2027 forecast to a $3.26 loss from $3.09. The firm also lowered its Q3 2026 estimate to a $0.93 loss from $0.65 and its Q4 estimate to a $0.87 loss from $0.75. The downward revisions indicate weaker expected financial performance.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.